b"LEARN MORE L a b P M M Browse Services Catalog online at invivoscribe.comC l i n i c a l L a b S e r v i c e sThe Laboratory for Personalized Molecular Medicine (LabPMM) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.NGS Cancer Panels thus providing more information for the patient. These Cytogenetic identification of chromosome abnormalitieshighly specific and sensitive techniques are utilized in has become essential for the clinical management ofscreening/diagnostic work up of leukemia/lymphomas patients with leukemia and is currently used to helpand rare event analysis such as minimal/measurable categorize patients into risk groups. disease (MRD) testing in various disease states such as Acute myeloid leukemia, Multiple myeloma and Chronic MRD NGS Tests lymphocytic leukemia. LabPMM's LymphoTrack MRD tests are NGS-basedCompanion Diagnostics (CDx) Testsassays that can be used to detect clonal geneThe fms related tyrosine kinase 3 (FLT3) is one of the rearrangements identified at diagnosis within virtuallymost commonly mutated genes in acute myeloid all of the antigen receptor loci for both B- and T-cells.leukemia (AML), occurring in approximately 30% of LabPMMs NPM1 MRD and FLT3 MRD tests are NGS- patients at the time of diagnosis. 1Although generally based assays that can be used to detect targetedassociated with normal cytogenetics where patients mutations identified at diagnosis. have standard risk of relapse, FLT3 mutations have Targeted Genes also been identified in sub-groups of patients with chromosomal abnormalities that are associated with FLT3 and NPM1 assays are offered to detect targetedhigh risk of disease relapse. 2-3mutations.L a b P M MCustom AssaysC l i n i c a l L a b S e r v i c e s Clonality Tests In response to the FDA announcing its intention The unique process of genetic rearrangements in theto dramatically expand its regulatory oversight of immunoglobulin (Ig) and T-cell receptor (TCR) genelaboratory developed tests (LDTs), Invivoscribe is The Laboratory for Personalized Molecularloci during immune cell development and maturationpartnering with laboratories worldwide to help facilitate Medicine (LabPMM) at Invivoscribe offergenerates a vast pool of genetically distinct cells. the conversion of LDTs into FDA-cleared assays, as we internationally standardized testing of novelknow the barriers to bringing new assays online are and proprietary biomarkers that are criticallyMultiparametric Flow Cytometry often the availability of resources and the costimportant for patient care. of validation. LabPMM offers standardized and sensitive Multi-Parameter Flow Cytometric Assays (MFC) that allowup to 14 parameters to be simultaneously analyzed ona single cell. Our advanced instrumentation and greater selection of fluorochromes allows us to collect more clinically relevant information with smaller sample sizes 1.Acute Myeloid Leukemia, Clinical Practice Guidelines in Oncology, (v.2.2014) National Comprehensive Cancer Network.2.Lowenberg, B. et al. (1999) Acute myeloid leukemia. N Engl J Med 341(14):1051-62.3.Thiede, C. et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: 12 association with FAB and identification of subgroups with poor prognosis. Blood 99(12): 4326-35. Invivoscribe 2021|13"